The European Commission authorised, on 10 November, a seventh vaccine against Covid-19: VidPrevtyn Beta. This vaccine was developed by Sanofi and GSK. The European Commission’s formal decision is based on a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), issued the same day. VidPrevtyn Beta is a recombinant protein vaccine formulated with the Beta variant antigen and adjuvanted with GSK’s pandemic adjuvant.
The vaccine is intended to be given as a booster dose to adults over 18 years of age who have already completed a first vaccination regimen against Covid-19, regardless of whether this first vaccination regimen was with an mRNA-based vaccine or an adenovirus vaccine
The CHMP considered that VidPrevtyn Beta could be as effective as the vaccine developed by Pfizer and BioNTech in restoring immunity against Covid-19.
Sanofi said that the doses of VidPrevtyn Beta vaccine are ready to be distributed to the Member States. An advance purchase agreement between the firm and the Commission came into force on 18 September 2020. The contract allows Member States to purchase up to 300 million doses of VidPrevtyn Beta.
Link to the list of authorised vaccines: https://aeur.eu/f/41o (Original version in French by Émilie Vanderhulst)